You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSertraline
Accession NumberDB01104  (APRD00175)
TypeSmall Molecule
GroupsApproved
DescriptionSertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Sertraline may be used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD) and social anxiety disorder (social phobia).
Structure
Thumb
Synonyms
(+)-Sertraline
(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
(1S,4S)-Sertraline
cis-(+)-Sertraline
CP 51974
Sertralina
Sertraline
Sertralinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Sertralinecapsule25 mgoralActavis Pharma Company2006-11-08Not applicableCanada
Act Sertralinecapsule50 mgoralActavis Pharma Company2006-11-08Not applicableCanada
Act Sertralinecapsule100 mgoralActavis Pharma Company2006-11-08Not applicableCanada
Auro-sertralinecapsule100 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-sertralinecapsule25 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-sertralinecapsule50 mgoralAuro Pharma Inc2012-10-18Not applicableCanada
Bio-sertralinecapsule50 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-sertralinecapsule100 mgoralBiomed PharmaNot applicableNot applicableCanada
Bio-sertralinecapsule25 mgoralBiomed PharmaNot applicableNot applicableCanada
Dom-sertralinecapsule25 mgoralDominion Pharmacal2002-05-31Not applicableCanada
Dom-sertralinecapsule50 mgoralDominion Pharmacal2002-05-31Not applicableCanada
Dom-sertralinecapsule100 mgoralDominion Pharmacal2002-05-31Not applicableCanada
Gd-sertralinecapsule25 mgoralGenmed A Division Of Pfizer Canada Inc2010-11-112016-05-31Canada
Gd-sertralinecapsule50 mgoralGenmed A Division Of Pfizer Canada Inc2010-11-112016-05-31Canada
Gd-sertralinecapsule100 mgoralGenmed A Division Of Pfizer Canada Inc2010-11-112016-05-31Canada
Ipg-sertralinecapsule25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-sertralinecapsule50 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-sertralinecapsule100 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-sertralinecapsule25 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-sertralinecapsule50 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-sertralinecapsule100 mgoralJamp Pharma Corporation2011-10-06Not applicableCanada
Mar-sertralinecapsule25 mgoralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mar-sertralinecapsule50 mgoralMarcan Pharmaceuticals Inc2014-01-06Not applicableCanada
Mar-sertralinecapsule100 mgoralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-sertralinecapsule25 mgoralMint Pharmaceuticals Inc2013-04-29Not applicableCanada
Mint-sertralinecapsule50 mgoralMint Pharmaceuticals Inc2013-04-29Not applicableCanada
Mint-sertralinecapsule100 mgoralMint Pharmaceuticals Inc2013-04-29Not applicableCanada
Mylan-sertralinecapsule100 mgoralMylan Pharmaceuticals Ulc2000-07-24Not applicableCanada
Mylan-sertralinecapsule25 mgoralMylan Pharmaceuticals Ulc2000-07-24Not applicableCanada
Mylan-sertralinecapsule50 mgoralMylan Pharmaceuticals Ulc2000-07-24Not applicableCanada
Nu-sertraline Capsulescapsule100 mgoralNu Pharm Inc2003-06-272012-09-04Canada
Nu-sertraline Capsulescapsule25 mgoralNu Pharm Inc2003-06-272012-09-04Canada
Nu-sertraline Capsulescapsule50 mgoralNu Pharm Inc2003-06-272012-09-04Canada
PHL-sertralinecapsule50 mgoralPharmel Inc2002-05-31Not applicableCanada
PHL-sertralinecapsule100 mgoralPharmel Inc2002-05-31Not applicableCanada
PHL-sertralinecapsule25 mgoralPharmel Inc2002-05-31Not applicableCanada
PMS-sertralinecapsule25 mgoralPharmascience Inc2002-01-30Not applicableCanada
PMS-sertralinecapsule50 mgoralPharmascience Inc2002-01-30Not applicableCanada
PMS-sertralinecapsule100 mgoralPharmascience Inc2002-01-30Not applicableCanada
Priva-sertralinecapsule100 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-sertralinecapsule25 mgoralPharmapar IncNot applicableNot applicableCanada
Priva-sertralinecapsule50 mgoralPharmapar IncNot applicableNot applicableCanada
Q-sertralinecapsule25 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-sertralinecapsule50 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-sertralinecapsule100 mgoralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Ran-sertralinecapsule25 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-11-24Not applicableCanada
Ran-sertralinecapsule50 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-11-24Not applicableCanada
Ran-sertralinecapsule100 mgoralRanbaxy Pharmaceuticals Canada Inc.2011-11-24Not applicableCanada
Ratio-sertralinecapsule50 mgoralRatiopharm Inc Division Of Teva Canada Limited2002-07-052014-09-24Canada
Ratio-sertralinecapsule100 mgoralRatiopharm Inc Division Of Teva Canada Limited2002-07-052014-09-19Canada
Ratio-sertralinecapsule25 mgoralRatiopharm Inc Division Of Teva Canada Limited2002-07-052014-09-19Canada
Riva-sertralinecapsule100 mgoralLaboratoire Riva Inc2005-01-10Not applicableCanada
Riva-sertralinecapsule25 mgoralLaboratoire Riva Inc2005-01-10Not applicableCanada
Riva-sertralinecapsule50 mgoralLaboratoire Riva Inc2005-10-01Not applicableCanada
Sandoz Sertralinecapsule25 mgoralSandoz Canada Incorporated2002-02-13Not applicableCanada
Sandoz Sertralinecapsule50 mgoralSandoz Canada Incorporated2002-02-13Not applicableCanada
Sandoz Sertralinecapsule100 mgoralSandoz Canada Incorporated2002-02-13Not applicableCanada
Sertralinecapsule50 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Sertralinecapsule50 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Sertralinecapsule25 mgoralMeliapharm Inc2010-10-122014-06-25Canada
Sertralinecapsule25 mgoralSanis Health Inc2010-08-03Not applicableCanada
Sertralinecapsule25 mgoralSanis Health Inc2009-10-222010-06-08Canada
Sertralinecapsule100 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Sertralinecapsule100 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Sertralinecapsule50 mgoralMeliapharm Inc2010-10-122014-06-25Canada
Sertralinecapsule50 mgoralSanis Health Inc2010-08-03Not applicableCanada
Sertralinecapsule50 mgoralSanis Health Inc2009-10-222010-06-08Canada
Sertralinecapsule100 mgoralMeliapharm Inc2010-10-122014-06-25Canada
Sertralinecapsule100 mgoralSanis Health Inc2010-08-03Not applicableCanada
Sertralinecapsule25 mgoralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
Sertralinecapsule25 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Sertralinecapsule100 mgoralSanis Health Inc2009-10-222010-06-08Canada
Sertraline Hydrochloridetablet, film coated25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-19Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralCardinal Health1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralContract Pharmacy Services Pa2010-03-15Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralGreenstone LLC1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralKAISER FOUNDATION HOSPITALS2012-01-06Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralPhysicians Total Care, Inc.2006-08-24Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2013-05-13Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralGreenstone LLC1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralPhysicians Total Care, Inc.2006-08-16Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
Sertraline Hydrochloridesolution, concentrate20 mg/mLoralGreenstone LLC1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralCardinal Health1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralPhysicians Total Care, Inc.2006-09-12Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralLife Line Home Care Services1992-02-11Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralGreenstone LLC1992-02-11Not applicableUs
Sertraline-100capsule100.0 mgoralPro Doc Limitee2001-02-15Not applicableCanada
Sertraline-25capsule25.0 mgoralPro Doc Limitee2001-02-15Not applicableCanada
Sertraline-50capsule50.0 mgoralPro Doc Limitee2001-02-15Not applicableCanada
Teva-sertralinecapsule100 mgoralTeva Canada Limited1999-08-16Not applicableCanada
Teva-sertralinecapsule50 mgoralTeva Canada Limited1999-08-16Not applicableCanada
Teva-sertralinecapsule25 mgoralTeva Canada Limited1999-08-16Not applicableCanada
Van-sertralinecapsule25 mgoralVanc Pharmaceuticals Inc2015-06-10Not applicableCanada
Van-sertralinecapsule50 mgoralVanc Pharmaceuticals Inc2015-06-10Not applicableCanada
Van-sertralinecapsule100 mgoralVanc Pharmaceuticals Inc2015-06-10Not applicableCanada
Zolofttablet, film coated50 mg/1oralRoerig1992-02-11Not applicableUs
Zolofttablet, film coated100 mg/1oralREMEDYREPACK INC.2013-02-25Not applicableUs
Zolofttablet, film coated50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs
Zolofttablet, film coated50 mg/1oralCardinal Health1992-02-11Not applicableUs
Zolofttablet, film coated100 mg/1oralAphena Pharma Solutions Tennessee, Llc1992-02-11Not applicableUs
Zolofttablet, film coated100 mg/1oralRoerig1992-02-11Not applicableUs
Zolofttablet, film coated100 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs
Zolofttablet, film coated50 mg/1oralSTAT Rx USA LLC1992-02-11Not applicableUs
Zoloftsolution, concentrate20 mg/mLoralRoerig1992-02-11Not applicableUs
Zolofttablet, film coated50 mg/1oralAphena Pharma Solutions Tennessee, Llc1992-02-11Not applicableUs
Zolofttablet, film coated100 mg/1oralSTAT Rx USA LLC1992-02-11Not applicableUs
Zoloftcapsule25 mgoralPfizer Canada Inc1995-12-31Not applicableCanada
Zolofttablet, film coated50 mg/1oralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Zolofttablet, film coated25 mg/1oralRoerig1992-02-11Not applicableUs
Zoloft Cap 100mgcapsule100 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Zoloft Cap 50mgcapsule50 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sertralinecapsule100 mgoralApotex Inc1999-09-01Not applicableCanada
Apo-sertralinecapsule25 mgoralApotex Inc1999-09-01Not applicableCanada
Apo-sertralinecapsule50 mgoralApotex Inc1999-09-01Not applicableCanada
Sertralinetablet, film coated100 mg/1oralREMEDYREPACK INC.2015-12-24Not applicableUs
Sertralinetablet, film coated50 mg/1oralReady Meds2012-11-06Not applicableUs
Sertralinetablet, film coated50 mg/1oralLupin Pharmaceuticals, Inc.2007-02-06Not applicableUs
Sertralinetablet100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-18Not applicableUs
Sertralinetablet, film coated50 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-08-20Not applicableUs
Sertralinetablet, film coated100 mg/1oralNorthwind Pharmaceuticals2014-05-27Not applicableUs
Sertralinetablet, film coated50 mg/1oralClinical Solutions Wholesale2007-02-06Not applicableUs
Sertralinetablet, film coated100 mg/1oralProficient Rx LP2007-02-06Not applicableUs
Sertralinetablet, film coated50 mg/1oralExelan Pharmaceuticals, Inc.2012-08-20Not applicableUs
Sertralinetablet, film coated50 mg/1oralWest ward Pharmaceutical Corp2012-11-06Not applicableUs
Sertralinetablet100 mg/1oralDIRECT RX2014-01-01Not applicableUs
Sertralinetablet, film coated100 mg/1oralLupin Pharmaceuticals, Inc.2007-02-06Not applicableUs
Sertralinetablet, film coated100 mg/1oralExelan Pharmaceuticals, Inc.2012-08-20Not applicableUs
Sertralinetablet, film coated100 mg/1oralClinical Solutions Wholesale2007-02-06Not applicableUs
Sertralinetablet, film coated25 mg/1oralProficient Rx LP2007-02-06Not applicableUs
Sertralinetablet, film coated25 mg/1oralWest ward Pharmaceutical Corp2012-11-06Not applicableUs
Sertralinetablet25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-18Not applicableUs
Sertralinetablet, film coated100 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-08-20Not applicableUs
Sertralinetablet50 mg/1oralDIRECT RX2014-01-01Not applicableUs
Sertralinetablet, film coated100 mg/1oralREMEDYREPACK INC.2015-04-14Not applicableUs
Sertralinetablet, film coated25 mg/1oralLupin Pharmaceuticals, Inc.2007-02-06Not applicableUs
Sertralinetablet50 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-18Not applicableUs
Sertralinetablet, film coated25 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-08-20Not applicableUs
Sertralinetablet, film coated50 mg/1oralNorthwind Pharmaceuticals, LLC2014-07-11Not applicableUs
Sertralinetablet50 mg/1oralInternational Labs, Inc.2012-02-20Not applicableUs
Sertralinetablet, film coated25 mg/1oralClinical Solutions Wholesale2007-02-06Not applicableUs
Sertralinetablet, film coated50 mg/1oralProficient Rx LP2007-02-06Not applicableUs
Sertralinetablet, film coated25 mg/1oralTYA Pharmaceuticals2007-02-06Not applicableUs
Sertralinetablet, film coated25 mg/1oralExelan Pharmaceuticals, Inc.2012-08-20Not applicableUs
Sertralinetablet, film coated100 mg/1oralWest ward Pharmaceutical Corp2012-11-06Not applicableUs
Sertralinetablet, film coated100 mg/1oralAidarex Pharmaceuticals LLC2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralClinical Solutions Wholesale, Llc2007-10-18Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralMc Kesson Contract Packaging2011-09-27Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.2013-05-29Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralPd Rx Pharmaceuticals, Inc.2009-08-10Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralMed Health Pharma, LLC2011-07-04Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2012-03-14Not applicableUs
Sertraline Hydrochloridesolution20 mg/mLoralNorth Star Rx Llc2008-10-31Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralREMEDYREPACK INC.2014-03-17Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralCardinal Health2007-12-182016-03-11Us
Sertraline Hydrochloridetablet, film coated100 mg/1oralHikma Pharmaceutical2009-08-10Not applicableUs
Sertraline Hydrochloridetablet, coated100 mg/1oralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralMed Vantx, Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralWest ward Pharmaceutical Corp2009-08-10Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralMajor Pharmaceuticals2013-05-15Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralCamber Pharmaceuticals Inc.2007-10-18Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralCobalt Laboratories Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-03-28Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralInternational Labs, Inc.2009-05-12Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralAurobindo Pharma Limited2007-02-06Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralCipla Limited2007-02-06Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralAurolife Pharma LLC2011-03-15Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-12-18Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralMylan Institutional Inc.2012-08-06Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralAccord Healthcare, Inc.2015-10-01Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralCardinal Health2007-02-01Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralSt Marys Medical Park Pharmacy2014-02-05Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralbryant ranch prepack2007-12-18Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralAmerican Health Packaging2011-04-06Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralAphena Pharma Solutions Tennessee, Inc.2012-02-03Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralMed Health Pharma, LLC2011-07-04Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralClinical Solutions Wholesale2007-10-18Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralTYA Pharmaceuticals2007-10-18Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralMc Kesson Contract Packaging2011-09-27Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.2013-05-18Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralMajor Pharmaceuticals2013-05-15Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralUnit Dose Services2007-12-18Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralNorth Star Rx Llc2007-02-06Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralH.J. Harkins Company Inc.2007-12-18Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralCardinal Health2007-12-182016-03-11Us
Sertraline Hydrochloridetablet, film coated25 mg/1oralApotex Corp2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, coated150 mg/1oralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralMed Vantx, Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-25Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralCardinal Health2010-12-15Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralWest ward Pharmaceutical Corp2009-08-10Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralSTAT Rx USA LLC2007-12-18Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralMedsource Pharmaceuticals2007-10-18Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralREMEDYREPACK INC.2013-03-27Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-02-15Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralInternational Labs, Inc.2009-05-10Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralAurobindo Pharma Limited2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralbryant ranch prepack2007-09-05Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralAmerican Health Packaging2010-12-15Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralCipla Limited2007-02-06Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralAurolife Pharma LLC2011-03-15Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-12-18Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralMylan Institutional Inc.2012-08-06Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralAccord Healthcare, Inc.2015-10-01Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralCardinal Health2007-02-01Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralSt Marys Medical Park Pharmacy2014-02-05Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralCobalt Laboratories Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralMed Health Pharma, LLC2011-07-04Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralClinical Solutions Wholesale2007-10-18Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralTYA Pharmaceuticals2007-10-18Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralKeltman Pharmaceuticals Inc.2011-09-09Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralMc Kesson Contract Packaging2011-09-27Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralWest ward Pharmaceutical Corp2009-08-10Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralMajor Pharmaceuticals2013-05-15Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralUnit Dose Services2007-12-18Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralNorth Star Rx Llc2007-02-06Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralH.J. Harkins Company Inc.2007-12-18Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralCardinal Health2013-07-05Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralApotex Corp2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, coated200 mg/1oralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralMed Vantx, Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-27Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2014-02-10Not applicableUs
Sertraline Hydrochloridetablet, coated25 mg/1oralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralAurobindo Pharma Limited2007-02-06Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralSTAT Rx USA LLC2007-12-18Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2011-03-28Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-05-06Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralCamber Pharmaceuticals Inc.2007-10-18Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralInternational Labs, Inc.2009-05-07Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralHikma Pharmaceutical2009-08-10Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralCardinal Health2007-02-01Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-12-01Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralCipla Limited2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.2013-05-29Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2007-01-02Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralMylan Institutional Inc.2012-08-06Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralAccord Healthcare, Inc.2015-10-01Not applicableUs
Sertraline Hydrochloridetablet, film coated25 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralCobalt Laboratories Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridetablet, film coated50 mg/1oralREMEDYREPACK INC.2013-02-28Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralAurolife Pharma LLC2011-03-15Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralUnit Dose Services2007-12-18Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralNorth Star Rx Llc2007-02-06Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralH.J. Harkins Company Inc.2007-12-18Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralCardinal Health2013-07-05Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralApotex Corp2007-02-06Not applicableUs
Sertraline Hydrochloridetablet100 mg/1oralbryant ranch prepack2007-12-18Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralAmerican Health Packaging2010-12-16Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralPreferred Pharmaceuticals, Inc.2012-02-27Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralCardinal Health2007-12-182016-03-11Us
Sertraline Hydrochloridetablet, film coated50 mg/1oralHikma Pharmaceutical2009-08-10Not applicableUs
Sertraline Hydrochloridetablet, coated50 mg/1oralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline Hydrochloridesolution, concentrate20 mg/mLoralAurobindo Pharma Limited2008-10-31Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralSTAT Rx USA LLC2007-12-18Not applicableUs
Sertraline Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2012-03-07Not applicableUs
Sertraline Hydrochloridetablet, film coated100 mg/1oralREMEDYREPACK INC.2014-02-26Not applicableUs
Sertraline Hydrochloridetablet50 mg/1oralCamber Pharmaceuticals Inc.2007-10-18Not applicableUs
Sertraline Hydrochloride Tabletstablet, film coated25 mg/1oralMajor Pharmaceuticals2009-11-10Not applicableUs
Sertraline Hydrochloride Tabletstablet, film coated50 mg/1oralMajor Pharmaceuticals2009-11-10Not applicableUs
Sertraline Hydrochloride Tabletstablet, film coated100 mg/1oralMajor Pharmaceuticals2009-11-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LustralNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sertraline Hydrochloride
Thumb
  • InChI Key: BLFQGGGGFNSJKA-XHXSRVRCSA-N
  • Monoisotopic Mass: 341.050482702
  • Average Mass: 342.691
DBSALT000808
Categories
UNIIQUC7NX6WMB
CAS number79617-96-2
WeightAverage: 306.23
Monoisotopic: 305.073804963
Chemical FormulaC17H17Cl2N
InChI KeyInChIKey=VGKDLMBJGBXTGI-SJCJKPOMSA-N
InChI
InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1
IUPAC Name
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
SMILES
CN[[email protected]]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tametralines. These are compounds containing a tametraline moiety, which consists of a tetrahydronaphthalene linked to a phenyl group to form N-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine skeleton.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTetralins
Sub ClassTametralines
Direct ParentTametralines
Alternative Parents
Substituents
  • Tametraline
  • 1,2-dichlorobenzene
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of major depressive disorder, posttraumatic stress disorder, obsessive-compulsive disorder, panic disorder with or without agoraphobia, premenstrual dysphoric disorder, social phobia, premature ejaculation, and vascular headaches.
PharmacodynamicsSertraline, an antidepressant drug similar to citalopram, fluoxetine, and paroxetine, is of the selective serotonin reuptake inhibitor (SSRI) type. Sertraline has one active metabolite and, like the other SSRIs, have less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not have clinically important anticholinergic, antihistamine, or adrenergic blocking activity.
Mechanism of actionThe exact mechanism of action sertraline is not fully known, but the drug appears to selectively inhibit the reuptake of serotonin at the presynaptic membrane. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission. It is suggested that these modifications are responsible for the antidepressant action observed during long term administration of antidepressants. It has also been hypothesized that obsessive-compulsive disorder is caused by the dysregulation of serotonin, as it is treated by sertraline, and the drug corrects this imbalance.
Related Articles
AbsorptionThe effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7.0 hours with food.
Volume of distributionNot Available
Protein binding98% bound to serum proteins, principally to albumin and α1-acid glycoprotein
Metabolism

Extensively metabolized in the liver. Sertraline metabolism involves N-demethylation, N-hydroxylation, oxidative deamination, and glucuronidation of sertraline carbamic acid. Sertraline undergoes N-demethylation primarily catalyzed by cytochrome P450 (CYP) 2B6, with CYP2C19, CYP3A4 and CYP2D6 contributing to a lesser extent. Deamination occurs via CYP3A4 and CYP2C19. In vitro studies have shown that monoamine oxidase A and B may also catalyze sertraline deamination. Sertraline N-carbamoyl glucuronidation has also been observed in human liver microsomes.

SubstrateEnzymesProduct
Sertraline
norsertralineDetails
Route of eliminationSertraline is extensively metabolized and excretion of unchanged drug in urine is a minor route of elimination.
Half lifeThe elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours.
ClearanceNot Available
ToxicitySymptoms of toxicity include alopecia, decreased libido, diarrhea, ejaculation disorder, fatigue, insomnia, somnolence and serotonin syndrome. The most frequently observed side effects include: GI effects such as nausea, diarrhea or loose stools, dyspepsia, and dry mouth; nervous system effects such as somnolence, dizziness, insomnia, and tremor; sexual dysfunction in males (principally ejaculatory delay); and sweating.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9713
Caco-2 permeable+0.6995
P-glycoprotein substrateNon-substrate0.5858
P-glycoprotein inhibitor IInhibitor0.7333
P-glycoprotein inhibitor IINon-inhibitor0.8319
Renal organic cation transporterNon-inhibitor0.6726
CYP450 2C9 substrateNon-substrate0.71
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6304
CYP450 1A2 substrateInhibitor0.7909
CYP450 2C9 inhibitorNon-inhibitor0.9307
CYP450 2D6 inhibitorNon-inhibitor0.6469
CYP450 2C19 inhibitorInhibitor0.6839
CYP450 3A4 inhibitorNon-inhibitor0.5442
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6633
Ames testAMES toxic0.5353
CarcinogenicityNon-carcinogens0.8499
BiodegradationNot ready biodegradable0.9522
Rat acute toxicity2.5020 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9151
hERG inhibition (predictor II)Inhibitor0.7185
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral100 mg/1
Tabletoral25 mg/1
Tabletoral50 mg/1
Solutionoral20 mg/mL
Tablet, coatedoral100 mg/1
Tablet, coatedoral150 mg/1
Tablet, coatedoral200 mg/1
Tablet, coatedoral25 mg/1
Tablet, coatedoral50 mg/1
Capsuleoral100.0 mg
Capsuleoral25.0 mg
Capsuleoral50.0 mg
Capsuleoral25 mg
Solution, concentrateoral20 mg/mL
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Capsuleoral100 mg
Capsuleoral50 mg
Prices
Unit descriptionCostUnit
Sertraline hcl powder480.0USD g
Zoloft 20 mg/ml Concentrate 60ml Bottle94.75USD bottle
Sertraline HCl 20 mg/ml Concentrate 60ml Bottle66.85USD bottle
Zoloft 50 mg tablet4.02USD tablet
Zoloft 100 mg tablet3.94USD tablet
Zoloft 25 mg tablet3.94USD tablet
Sertraline hcl 100 mg tablet2.77USD tablet
Sertraline hcl 25 mg tablet2.77USD tablet
Sertraline hcl 50 mg tablet2.77USD tablet
Zoloft 100 mg Capsule1.9USD capsule
Zoloft 50 mg Capsule1.81USD capsule
Apo-Sertraline 100 mg Capsule1.06USD capsule
Co Sertraline 100 mg Capsule1.06USD capsule
Mylan-Sertraline 100 mg Capsule1.06USD capsule
Novo-Sertraline 100 mg Capsule1.06USD capsule
Phl-Sertraline 100 mg Capsule1.06USD capsule
Pms-Sertraline 100 mg Capsule1.06USD capsule
Ratio-Sertraline 100 mg Capsule1.06USD capsule
Sandoz Sertraline 100 mg Capsule1.06USD capsule
Sertraline 100 mg Capsule1.06USD capsule
Apo-Sertraline 50 mg Capsule1.01USD capsule
Co Sertraline 50 mg Capsule1.01USD capsule
Mylan-Sertraline 50 mg Capsule1.01USD capsule
Novo-Sertraline 50 mg Capsule1.01USD capsule
Phl-Sertraline 50 mg Capsule1.01USD capsule
Pms-Sertraline 50 mg Capsule1.01USD capsule
Ratio-Sertraline 50 mg Capsule1.01USD capsule
Sandoz Sertraline 50 mg Capsule1.01USD capsule
Sertraline 50 mg Capsule1.01USD capsule
Zoloft 25 mg Capsule0.91USD capsule
Apo-Sertraline 25 mg Capsule0.51USD capsule
Co Sertraline 25 mg Capsule0.51USD capsule
Mylan-Sertraline 25 mg Capsule0.51USD capsule
Novo-Sertraline 25 mg Capsule0.51USD capsule
Phl-Sertraline 25 mg Capsule0.51USD capsule
Pms-Sertraline 25 mg Capsule0.51USD capsule
Ratio-Sertraline 25 mg Capsule0.51USD capsule
Sandoz Sertraline 25 mg Capsule0.51USD capsule
Sertraline 25 mg Capsule0.51USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2029065 No1994-11-082010-10-31Canada
US4962128 No1992-11-022009-11-02Us
US6727283 Yes2000-04-112020-04-11Us
US7067555 Yes2000-04-112020-04-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point243-245 °CNot Available
water solubility3.5mg/LNot Available
logP5.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000145 mg/mLALOGPS
logP5.06ALOGPS
logP5.15ChemAxon
logS-6.3ALOGPS
pKa (Strongest Basic)9.85ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity85.74 m3·mol-1ChemAxon
Polarizability32.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00b9-2890000000-d53a90b04ec8457ad2f1View in MoNA
References
Synthesis Reference

George J. Quallich, Michael T. Williams, “Process for preparing sertraline intermediates.” U.S. Patent US4839104, issued February, 1977.

US4839104
General References
  1. Couzin J: The brains behind blockbusters. Science. 2005 Jul 29;309(5735):728. [PubMed:16051786 ]
  2. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG: Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995 Nov 1;38(9):592-602. [PubMed:8573661 ]
  3. Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, Roy-Byrne P, Phillips K, Du Pont IJ: Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol. 1999 Apr;19(2):172-6. [PubMed:10211919 ]
  4. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000 Apr 12;283(14):1837-44. [PubMed:10770145 ]
  5. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W: Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997 Sep 24;278(12):983-8. [PubMed:9307345 ]
  6. Shelton RC: The role of sertraline in the management of depression. Clin Ther. 1994 Sep-Oct;16(5):768-82; discussion 767. [PubMed:7859236 ]
  7. Murdoch D, McTavish D: Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 1992 Oct;44(4):604-24. [PubMed:1281075 ]
External Links
ATC CodesN06AB06
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (98.7 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Sertraline.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Sertraline.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Sertraline.
AbirateroneThe serum concentration of Sertraline can be increased when it is combined with Abiraterone.
AcarboseSertraline may increase the hypoglycemic activities of Acarbose.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Sertraline.
AcenocoumarolSertraline may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sertraline.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Sertraline.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Sertraline.
AcetophenazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Sertraline.
Acetylsalicylic acidSertraline may increase the antiplatelet activities of Acetylsalicylic acid.
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Sertraline.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Sertraline.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Sertraline.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Sertraline.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Sertraline.
AlbiglutideSertraline may increase the hypoglycemic activities of Albiglutide.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Sertraline.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Sertraline.
AlfentanilAlfentanil may increase the serotonergic activities of Sertraline.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Sertraline.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Sertraline.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Sertraline.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sertraline.
AlogliptinSertraline may increase the hypoglycemic activities of Alogliptin.
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Sertraline.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sertraline.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Sertraline.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Sertraline.
AmineptineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amineptine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sertraline.
AmiodaroneThe metabolism of Amiodarone can be decreased when combined with Sertraline.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Sertraline.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Sertraline.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Sertraline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sertraline.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sertraline.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Sertraline.
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Sertraline.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Sertraline.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Sertraline.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Sertraline.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Sertraline.
AnagrelideSertraline may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sertraline.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Sertraline.
AprepitantThe serum concentration of Sertraline can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be decreased when combined with Sertraline.
AprindineThe metabolism of Aprindine can be decreased when combined with Sertraline.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sertraline.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sertraline.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sertraline.
ArmodafinilThe metabolism of Sertraline can be decreased when combined with Armodafinil.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Sertraline.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Sertraline.
ArtemetherThe metabolism of Artemether can be decreased when combined with Sertraline.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Sertraline.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Sertraline.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Sertraline.
AtazanavirThe metabolism of Sertraline can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Sertraline.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Sertraline.
AtomoxetineThe metabolism of Sertraline can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Sertraline.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Sertraline.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Sertraline.
AzelastineThe metabolism of Azelastine can be decreased when combined with Sertraline.
AzithromycinSertraline may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Sertraline can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Sertraline.
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Sertraline.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Sertraline.
BedaquilineSertraline may increase the QTc-prolonging activities of Bedaquiline.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Sertraline.
BendroflumethiazideSertraline may increase the hyponatremic activities of Bendroflumethiazide.
BenmoxinBenmoxin may increase the serotonergic activities of Sertraline.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Sertraline.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sertraline.
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Sertraline.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Sertraline.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Sertraline.
BepridilThe metabolism of Bepridil can be decreased when combined with Sertraline.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Sertraline.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Sertraline.
BetaxololThe metabolism of Sertraline can be decreased when combined with Betaxolol.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Sertraline.
BexaroteneThe serum concentration of Sertraline can be decreased when it is combined with Bexarotene.
BezitramideBezitramide may increase the serotonergic activities of Sertraline.
BifeprunoxThe risk or severity of adverse effects can be increased when Sertraline is combined with Bifeprunox.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Sertraline.
BoceprevirThe metabolism of Sertraline can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Sertraline.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Sertraline.
BortezomibThe metabolism of Sertraline can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Sertraline can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sertraline.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sertraline.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Sertraline.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Sertraline.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sertraline.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Sertraline.
BromazepamThe metabolism of Bromazepam can be decreased when combined with Sertraline.
BromocriptineSertraline may increase the hypoglycemic activities of Bromocriptine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sertraline.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Sertraline.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sertraline.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Sertraline.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Sertraline.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sertraline.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Sertraline.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Sertraline.
BuprenorphineBuprenorphine may increase the serotonergic activities of Sertraline.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sertraline.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Sertraline.
BupropionThe metabolism of Sertraline can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sertraline.
BuspironeThe metabolism of Buspirone can be decreased when combined with Sertraline.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sertraline.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Sertraline.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Sertraline.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Sertraline.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Sertraline.
ButorphanolButorphanol may increase the serotonergic activities of Sertraline.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Sertraline.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sertraline.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Sertraline.
CaffeineThe metabolism of Sertraline can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Sertraline.
CanagliflozinSertraline may increase the hypoglycemic activities of Canagliflozin.
CapecitabineThe metabolism of Sertraline can be decreased when combined with Capecitabine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Sertraline.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sertraline.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Sertraline.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Sertraline.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sertraline.
CarfentanilCarfentanil may increase the serotonergic activities of Sertraline.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Sertraline.
CariprazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Sertraline.
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Sertraline.
CaroxazoneCaroxazone may increase the serotonergic activities of Sertraline.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Sertraline.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sertraline.
CelecoxibThe metabolism of Sertraline can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Sertraline.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Sertraline.
CeritinibThe serum concentration of Sertraline can be increased when it is combined with Ceritinib.
CeritinibSertraline may increase the QTc-prolonging activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Sertraline.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Sertraline.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Sertraline.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sertraline.
ChloramphenicolThe metabolism of Sertraline can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sertraline.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Sertraline.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Sertraline.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sertraline.
ChloroquineSertraline may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Sertraline can be decreased when combined with Chloroquine.
ChlorothiazideSertraline may increase the hyponatremic activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Sertraline.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Sertraline.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sertraline.
ChlorpropamideSertraline may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sertraline.
ChlorthalidoneSertraline may increase the hyponatremic activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Sertraline.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Sertraline.
CholecalciferolThe metabolism of Sertraline can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Sertraline.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Sertraline.
CimetidineThe metabolism of Sertraline can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Sertraline can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sertraline.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sertraline.
CiprofloxacinSertraline may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideThe metabolism of Cisapride can be decreased when combined with Sertraline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Sertraline.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Sertraline.
CitalopramThe metabolism of Sertraline can be decreased when combined with Citalopram.
ClarithromycinSertraline may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Sertraline can be decreased when combined with Clarithromycin.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Sertraline.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Sertraline.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Sertraline.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Sertraline.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Sertraline.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Sertraline.
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Sertraline.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Sertraline.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Sertraline.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Sertraline.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Sertraline.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Sertraline.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Sertraline.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Sertraline.
ClopidogrelThe metabolism of Sertraline can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertraline.
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Sertraline.
ClotrimazoleThe metabolism of Sertraline can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sertraline.
CobicistatThe serum concentration of Sertraline can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Sertraline.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Sertraline.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Sertraline.
CodeineCodeine may increase the serotonergic activities of Sertraline.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Sertraline.
ConivaptanThe serum concentration of Sertraline can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sertraline.
CrizotinibSertraline may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Sertraline can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Sertraline.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertraline.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Sertraline.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Sertraline.
CyclosporineThe metabolism of Sertraline can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Sertraline.
CyproheptadineThe therapeutic efficacy of Sertraline can be decreased when used in combination with Cyproheptadine.
Cyproterone acetateThe serum concentration of Sertraline can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Sertraline.
DabrafenibThe serum concentration of Sertraline can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Sertraline.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Sertraline.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sertraline.
DapagliflozinSertraline may increase the hypoglycemic activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sertraline.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Sertraline.
DapoxetineSertraline may increase the serotonergic activities of Dapoxetine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Sertraline.
DarifenacinThe metabolism of Sertraline can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Sertraline can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Sertraline.
DasatinibThe serum concentration of Sertraline can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Sertraline.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Sertraline.
DeferasiroxThe serum concentration of Sertraline can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Sertraline can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Sertraline.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sertraline.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Sertraline.
DesipramineThe metabolism of Desipramine can be decreased when combined with Sertraline.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sertraline.
DesmopressinThe risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Sertraline.
DexamethasoneThe serum concentration of Sertraline can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Sertraline.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Sertraline.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sertraline.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Sertraline.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Sertraline.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Sertraline.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sertraline.
DextromoramideDextromoramide may increase the serotonergic activities of Sertraline.
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Sertraline.
DezocineDezocine may increase the serotonergic activities of Sertraline.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Sertraline.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Sertraline.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Sertraline.
DicoumarolSertraline may increase the anticoagulant activities of Dicoumarol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sertraline.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Sertraline.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Sertraline.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sertraline.
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Sertraline.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Sertraline.
DihydroergotamineThe metabolism of Sertraline can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Sertraline is combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Sertraline.
DihydromorphineDihydromorphine may increase the serotonergic activities of Sertraline.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Sertraline.
DiltiazemThe metabolism of Sertraline can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Sertraline.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sertraline.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sertraline.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Sertraline.
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Sertraline.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Sertraline.
DisopyramideSertraline may increase the hypoglycemic activities of Disopyramide.
DisulfiramThe risk or severity of adverse effects can be increased when Disulfiram is combined with Sertraline.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Sertraline.
DofetilideSertraline may increase the QTc-prolonging activities of Dofetilide.
DolasetronSertraline may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Sertraline.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Sertraline.
DonepezilThe metabolism of Donepezil can be decreased when combined with Sertraline.
DopamineThe metabolism of Dopamine can be decreased when combined with Sertraline.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Sertraline.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Sertraline.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Sertraline.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Sertraline.
DoxepinThe metabolism of Doxepin can be decreased when combined with Sertraline.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sertraline.
DoxorubicinThe metabolism of Sertraline can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Sertraline can be decreased when combined with Doxycycline.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Sertraline.
DPDPEDPDPE may increase the serotonergic activities of Sertraline.
DronabinolThe metabolism of Dronabinol can be decreased when combined with Sertraline.
DronedaroneThe metabolism of Sertraline can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Sertraline.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Sertraline.
DulaglutideSertraline may increase the hypoglycemic activities of Dulaglutide.
DuloxetineThe metabolism of Sertraline can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Sertraline.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Sertraline.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Sertraline.
EfavirenzThe serum concentration of Sertraline can be decreased when it is combined with Efavirenz.
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Sertraline.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Sertraline.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sertraline.
EliglustatThe metabolism of Eliglustat can be decreased when combined with Sertraline.
EmpagliflozinSertraline may increase the hypoglycemic activities of Empagliflozin.
EncainideThe metabolism of Encainide can be decreased when combined with Sertraline.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Sertraline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sertraline.
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Sertraline.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Sertraline.
EnzalutamideThe serum concentration of Sertraline can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Sertraline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertraline.
ErgonovineThe risk or severity of adverse effects can be increased when Sertraline is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sertraline.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Sertraline.
ErythromycinSertraline may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Sertraline can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the serotonergic activities of Sertraline.
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Sertraline.
Eslicarbazepine acetateThe serum concentration of Sertraline can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Sertraline.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Sertraline.
EsomeprazoleThe metabolism of Sertraline can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Sertraline.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Sertraline.
EstriolThe serum concentration of Estriol can be increased when it is combined with Sertraline.
EstroneThe serum concentration of Estrone can be increased when it is combined with Sertraline.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sertraline.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Sertraline.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertraline.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sertraline.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertraline.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sertraline.
Ethyl biscoumacetateSertraline may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertraline.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sertraline.
EthylmorphineEthylmorphine may increase the serotonergic activities of Sertraline.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Sertraline.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Sertraline.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Sertraline.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Sertraline.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertraline.
EtoperidoneSertraline may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Sertraline.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Sertraline.
EtorphineEtorphine may increase the serotonergic activities of Sertraline.
EtravirineThe serum concentration of Sertraline can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be decreased when combined with Sertraline.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sertraline.
ExenatideSertraline may increase the hypoglycemic activities of Exenatide.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Sertraline.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Sertraline.
FamotidineThe metabolism of Famotidine can be decreased when combined with Sertraline.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Sertraline.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Sertraline.
FenfluramineFenfluramine may increase the serotonergic activities of Sertraline.
FentanylFentanyl may increase the serotonergic activities of Sertraline.
FentanylThe risk or severity of adverse effects can be increased when Sertraline is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sertraline.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Sertraline.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Sertraline.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Sertraline.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Sertraline.
FlecainideSertraline may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sertraline.
FloxuridineThe metabolism of Sertraline can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Sertraline can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertraline.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Sertraline.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sertraline.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Sertraline.
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sertraline.
FluorouracilThe metabolism of Sertraline can be decreased when combined with Fluorouracil.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Sertraline.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sertraline.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sertraline.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sertraline.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertraline.
FlutamideThe metabolism of Flutamide can be decreased when combined with Sertraline.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Sertraline.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Sertraline.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sertraline.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sertraline.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Sertraline.
FormoterolThe metabolism of Formoterol can be decreased when combined with Sertraline.
FosamprenavirThe metabolism of Sertraline can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Sertraline can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Sertraline can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Sertraline.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Sertraline.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Sertraline.
FurazolidoneFurazolidone may increase the serotonergic activities of Sertraline.
Fusidic AcidThe serum concentration of Sertraline can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sertraline.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Sertraline.
Gadobenic acidSertraline may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineThe metabolism of Galantamine can be decreased when combined with Sertraline.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Sertraline.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Sertraline.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Sertraline.
GemfibrozilThe metabolism of Sertraline can be decreased when combined with Gemfibrozil.
GemifloxacinSertraline may increase the QTc-prolonging activities of Gemifloxacin.
GliclazideSertraline may increase the hypoglycemic activities of Gliclazide.
GlimepirideSertraline may increase the hypoglycemic activities of Glimepiride.
GlipizideSertraline may increase the hypoglycemic activities of Glipizide.
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Sertraline.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Sertraline.
GlyburideSertraline may increase the hypoglycemic activities of Glyburide.
GoserelinSertraline may increase the QTc-prolonging activities of Goserelin.
GranisetronSertraline may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Sertraline.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Sertraline.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Sertraline.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sertraline.
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Sertraline.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Sertraline.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Sertraline.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sertraline.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Sertraline.
HalothaneThe metabolism of Halothane can be decreased when combined with Sertraline.
HeroinHeroin may increase the serotonergic activities of Sertraline.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Sertraline.
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sertraline.
HydracarbazineHydracarbazine may increase the serotonergic activities of Sertraline.
HydrochlorothiazideSertraline may increase the hyponatremic activities of Hydrochlorothiazide.
HydrocodoneHydrocodone may increase the serotonergic activities of Sertraline.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Sertraline.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Sertraline.
HydroflumethiazideSertraline may increase the hyponatremic activities of Hydroflumethiazide.
HydromorphoneHydromorphone may increase the serotonergic activities of Sertraline.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sertraline.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Sertraline.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Sertraline.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Sertraline.
IbutilideSertraline may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sertraline.
IdelalisibThe serum concentration of Sertraline can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Sertraline.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Sertraline.
ImatinibThe metabolism of Sertraline can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Sertraline.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Sertraline.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Sertraline.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Sertraline.
IndalpineSertraline may increase the serotonergic activities of Indalpine.
IndapamideSertraline may increase the hyponatremic activities of Indapamide.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Sertraline.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Sertraline.
IndinavirThe metabolism of Sertraline can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Sertraline.
Insulin AspartSertraline may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirSertraline may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineSertraline may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineSertraline may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanSertraline may increase the hypoglycemic activities of Insulin Human.
Insulin LisproSertraline may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123Sertraline may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Sertraline.
IproclozideIproclozide may increase the serotonergic activities of Sertraline.
IproniazidIproniazid may increase the serotonergic activities of Sertraline.
IrbesartanThe metabolism of Sertraline can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Sertraline.
IsavuconazoniumThe metabolism of Sertraline can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Sertraline.
IsocarboxazidThe risk or severity of adverse effects can be increased when Sertraline is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Sertraline.
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Sertraline.
IsoniazidThe metabolism of Sertraline can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Sertraline can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Sertraline can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Sertraline can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Sertraline.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Sertraline.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sertraline.
KetamineThe metabolism of Ketamine can be decreased when combined with Sertraline.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Sertraline.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Sertraline.
KetobemidoneKetobemidone may increase the serotonergic activities of Sertraline.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sertraline.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Sertraline.
KetoconazoleThe metabolism of Sertraline can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Sertraline.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Sertraline.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Sertraline.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sertraline.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Sertraline.
LanreotideSertraline may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Sertraline.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Sertraline.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Sertraline.
LeflunomideThe metabolism of Sertraline can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Sertraline.
LenvatinibSertraline may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideSertraline may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sertraline.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Sertraline.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Sertraline.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Sertraline.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Sertraline.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sertraline.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Sertraline.
LevodopaThe metabolism of Levodopa can be decreased when combined with Sertraline.
LevofloxacinSertraline may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Sertraline.
LevomilnacipranLevomilnacipran may increase the serotonergic activities of Sertraline.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Sertraline.
LevorphanolLevorphanol may increase the serotonergic activities of Sertraline.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Sertraline.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sertraline.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Sertraline.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Sertraline.
LinezolidLinezolid may increase the serotonergic activities of Sertraline.
LinezolidThe risk or severity of adverse effects can be increased when Sertraline is combined with Linezolid.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Sertraline.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Sertraline.
LiraglutideSertraline may increase the hypoglycemic activities of Liraglutide.
LisurideThe metabolism of Lisuride can be decreased when combined with Sertraline.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Sertraline.
LofentanilLofentanil may increase the serotonergic activities of Sertraline.
LomustineThe metabolism of Lomustine can be decreased when combined with Sertraline.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Sertraline.
LopinavirThe metabolism of Sertraline can be decreased when combined with Lopinavir.
LopinavirSertraline may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Sertraline.
LoratadineThe metabolism of Loratadine can be decreased when combined with Sertraline.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sertraline.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Sertraline.
LosartanThe serum concentration of Losartan can be increased when it is combined with Sertraline.
LosartanThe metabolism of Sertraline can be decreased when combined with Losartan.
LovastatinThe metabolism of Sertraline can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sertraline.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Sertraline.
Lu AA21004Sertraline may increase the serotonergic activities of Lu AA21004.
LuliconazoleThe serum concentration of Sertraline can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Sertraline can be decreased when it is combined with Lumacaftor.
LumefantrineSertraline may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Sertraline can be decreased when combined with Lumefantrine.
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Sertraline.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Sertraline.
MacitentanThe metabolism of Macitentan can be decreased when combined with Sertraline.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Sertraline.
MalathionThe metabolism of Malathion can be decreased when combined with Sertraline.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Sertraline.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Sertraline.
MebanazineMebanazine may increase the serotonergic activities of Sertraline.
MecaserminSertraline may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Sertraline.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Sertraline.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Sertraline.
MelatoninThe metabolism of Melatonin can be decreased when combined with Sertraline.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Sertraline.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sertraline.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertraline.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sertraline.
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Sertraline.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Sertraline.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sertraline.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sertraline.
MetforminSertraline may increase the hypoglycemic activities of Metformin.
MethadoneMethadone may increase the serotonergic activities of Sertraline.
MethadoneSertraline may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Sertraline.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Sertraline.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sertraline.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Sertraline.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sertraline.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sertraline.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Sertraline.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Sertraline.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sertraline.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sertraline.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sertraline.
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Sertraline.
MethyclothiazideSertraline may increase the hyponatremic activities of Methyclothiazide.
Methylene blueSertraline may increase the serotonergic activities of Methylene blue.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Sertraline.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sertraline.
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Sertraline.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Sertraline.
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Sertraline.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Sertraline.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Sertraline.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertraline.
MetolazoneSertraline may increase the hyponatremic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Sertraline.
MetoprololThe metabolism of Sertraline can be decreased when combined with Metoprolol.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Sertraline.
MexiletineThe metabolism of Sertraline can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Sertraline.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sertraline.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Sertraline.
MifepristoneSertraline may increase the hypoglycemic activities of Mifepristone.
MifepristoneThe metabolism of Sertraline can be decreased when combined with Mifepristone.
MiglitolSertraline may increase the hypoglycemic activities of Miglitol.
MilnacipranSertraline may increase the serotonergic activities of Milnacipran.
MinaprineMinaprine may increase the serotonergic activities of Sertraline.
MinaprineThe metabolism of Minaprine can be decreased when combined with Sertraline.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Sertraline.
MirabegronThe metabolism of Sertraline can be decreased when combined with Mirabegron.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sertraline.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Sertraline.
MitotaneThe serum concentration of Sertraline can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Sertraline.
MoclobemideMoclobemide may increase the serotonergic activities of Sertraline.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Sertraline.
ModafinilThe serum concentration of Sertraline can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Sertraline.
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Sertraline.
MorphineMorphine may increase the serotonergic activities of Sertraline.
MorphineThe serum concentration of Morphine can be increased when it is combined with Sertraline.
MoxifloxacinSertraline may increase the QTc-prolonging activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sertraline.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Sertraline.
NadololThe serum concentration of Nadolol can be increased when it is combined with Sertraline.
NafcillinThe serum concentration of Sertraline can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the serotonergic activities of Sertraline.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sertraline.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Sertraline.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sertraline.
NateglinideSertraline may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Sertraline.
NefazodoneThe metabolism of Sertraline can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Sertraline.
NelfinavirThe metabolism of Sertraline can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Sertraline can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Sertraline.
NevirapineThe metabolism of Sertraline can be decreased when combined with Nevirapine.
NialamideNialamide may increase the serotonergic activities of Sertraline.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Sertraline.
NicardipineThe metabolism of Sertraline can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Sertraline.
NicotineThe metabolism of Nicotine can be decreased when combined with Sertraline.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Sertraline.
NilotinibThe metabolism of Sertraline can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Sertraline.
NilutamideThe metabolism of Nilutamide can be decreased when combined with Sertraline.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Sertraline.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertraline.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Sertraline.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Sertraline.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Sertraline.
NormethadoneNormethadone may increase the serotonergic activities of Sertraline.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Sertraline.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Sertraline.
OctamoxinOctamoxin may increase the serotonergic activities of Sertraline.
OctreotideSertraline may increase the hypoglycemic activities of Octreotide.
OfloxacinSertraline may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sertraline.
OlaparibThe metabolism of Sertraline can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sertraline.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Sertraline.
OmeprazoleThe metabolism of Sertraline can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sertraline.
OpiumOpium may increase the serotonergic activities of Sertraline.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sertraline.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Sertraline.
OsimertinibThe serum concentration of Sertraline can be increased when it is combined with Osimertinib.
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Sertraline.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sertraline.
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Sertraline.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Sertraline.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Sertraline.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sertraline.
OxycodoneOxycodone may increase the serotonergic activities of Sertraline.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Sertraline.
OxymorphoneOxymorphone may increase the serotonergic activities of Sertraline.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Sertraline.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Sertraline.
PalbociclibThe serum concentration of Sertraline can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Sertraline.
PalonosetronPalonosetron may increase the serotonergic activities of Sertraline.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Sertraline.
PanobinostatSertraline may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Sertraline can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Sertraline can be decreased when combined with Pantoprazole.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Sertraline.
PargylinePargyline may increase the serotonergic activities of Sertraline.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Sertraline.
PasireotideSertraline may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sertraline.
Peginterferon alfa-2bThe serum concentration of Sertraline can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Sertraline.
PentamidineSertraline may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Sertraline.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sertraline.
PentobarbitalThe metabolism of Pentobarbital can be decreased when combined with Sertraline.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Sertraline.
PerflutrenSertraline may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Sertraline.
PermethrinThe metabolism of Permethrin can be decreased when combined with Sertraline.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Sertraline.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sertraline.
PethidinePethidine may increase the serotonergic activities of Sertraline.
PethidineThe metabolism of Pethidine can be decreased when combined with Sertraline.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sertraline.
PhenelzinePhenelzine may increase the serotonergic activities of Sertraline.
PhenelzineThe risk or severity of adverse effects can be increased when Sertraline is combined with Phenelzine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Sertraline.
PhenindioneSertraline may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the serotonergic activities of Sertraline.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sertraline.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Sertraline.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Sertraline.
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Sertraline.
PhenprocoumonSertraline may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Sertraline.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Sertraline.
PimozideThe risk or severity of adverse effects can be increased when Sertraline is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Sertraline.
PioglitazoneSertraline may increase the hypoglycemic activities of Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sertraline.
PiperazineThe metabolism of Piperazine can be decreased when combined with Sertraline.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Sertraline.
PirlindolePirlindole may increase the serotonergic activities of Sertraline.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Sertraline.
PivhydrazinePivhydrazine may increase the serotonergic activities of Sertraline.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Sertraline.
PodofiloxThe metabolism of Podofilox can be decreased when combined with Sertraline.
PolythiazideSertraline may increase the hyponatremic activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sertraline.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Sertraline.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Sertraline.
PosaconazoleThe metabolism of Sertraline can be decreased when combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Sertraline.
PramlintideSertraline may increase the hypoglycemic activities of Pramlintide.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Sertraline.
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sertraline.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Sertraline.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline.
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Sertraline.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Sertraline.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Sertraline.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Sertraline.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sertraline.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Sertraline.
PrimaquineSertraline may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Sertraline.
PrimidoneThe metabolism of Primidone can be decreased when combined with Sertraline.
ProcainamideThe metabolism of Procainamide can be decreased when combined with Sertraline.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Sertraline.
ProcarbazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Procarbazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertraline.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Sertraline.
ProguanilThe metabolism of Proguanil can be decreased when combined with Sertraline.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sertraline.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Sertraline.
PromethazineThe metabolism of Promethazine can be decreased when combined with Sertraline.
PropafenoneThe serum concentration of Sertraline can be increased when it is combined with Propafenone.
PropafenoneSertraline may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sertraline.
PropericiazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Sertraline.
PropofolThe metabolism of Propofol can be decreased when combined with Sertraline.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Sertraline.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Sertraline.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sertraline.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Sertraline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Sertraline.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Sertraline.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Sertraline.
PyrimethamineThe metabolism of Sertraline can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Sertraline can be increased when it is combined with Quazepam.
QuazepamThe metabolism of Quazepam can be decreased when combined with Sertraline.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sertraline.
QuinethazoneSertraline may increase the hyponatremic activities of Quinethazone.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Sertraline.
QuinidineThe metabolism of Sertraline can be decreased when combined with Quinidine.
QuinineSertraline may increase the hypoglycemic activities of Quinine.
QuinineThe metabolism of Sertraline can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Sertraline.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Sertraline.
RamelteonThe metabolism of Ramelteon can be decreased when combined with Sertraline.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Sertraline.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Sertraline.
RanolazineThe metabolism of Sertraline can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the serotonergic activities of Sertraline.
RasagilineThe risk or severity of adverse effects can be increased when Sertraline is combined with Rasagiline.
RemifentanilRemifentanil may increase the serotonergic activities of Sertraline.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sertraline.
RepaglinideSertraline may increase the hypoglycemic activities of Repaglinide.
repinotanThe metabolism of repinotan can be decreased when combined with Sertraline.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sertraline.
RifabutinThe metabolism of Sertraline can be increased when combined with Rifabutin.
RifampicinThe metabolism of Sertraline can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Sertraline.
RifapentineThe metabolism of Sertraline can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Sertraline.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Sertraline.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sertraline.
RitonavirThe metabolism of Sertraline can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Sertraline.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Sertraline.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sertraline.
RolapitantThe metabolism of Sertraline can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Sertraline.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Sertraline.
RopiniroleThe metabolism of Sertraline can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sertraline.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Sertraline.
RosiglitazoneSertraline may increase the hypoglycemic activities of Rosiglitazone.
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sertraline.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Sertraline.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sertraline.
SafrazineSafrazine may increase the serotonergic activities of Sertraline.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Sertraline.
SaquinavirSertraline may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Sertraline can be decreased when combined with Saquinavir.
SaxagliptinSertraline may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sertraline.
SelegilineSelegiline may increase the serotonergic activities of Sertraline.
SelegilineThe metabolism of Selegiline can be decreased when combined with Sertraline.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Sertraline.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sertraline.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sertraline.
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Sertraline.
SildenafilThe metabolism of Sertraline can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Sertraline.
SiltuximabThe serum concentration of Sertraline can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Sertraline can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Sertraline.
SitagliptinSertraline may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Sertraline.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Sertraline.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Sertraline.
SorafenibThe metabolism of Sertraline can be decreased when combined with Sorafenib.
SotalolThe serum concentration of Sotalol can be increased when it is combined with Sertraline.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Sertraline.
SparteineThe metabolism of Sparteine can be decreased when combined with Sertraline.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Sertraline.
St. John's WortThe serum concentration of Sertraline can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Sertraline.
SufentanilSufentanil may increase the serotonergic activities of Sertraline.
SulfadiazineSertraline may increase the hypoglycemic activities of Sulfadiazine.
SulfadiazineThe metabolism of Sertraline can be decreased when combined with Sulfadiazine.
SulfamethoxazoleSertraline may increase the hypoglycemic activities of Sulfamethoxazole.
SulfamethoxazoleThe metabolism of Sertraline can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleSertraline may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Sertraline can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sertraline.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sertraline.
SunitinibSertraline may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Sertraline.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Sertraline.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Sertraline.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Sertraline.
TapentadolTapentadol may increase the serotonergic activities of Sertraline.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Sertraline.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Sertraline.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Sertraline.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Sertraline.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Sertraline.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Sertraline is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Sertraline.
TelaprevirThe metabolism of Sertraline can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Sertraline.
TelavancinSertraline may increase the QTc-prolonging activities of Telavancin.
TelithromycinSertraline may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Sertraline can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sertraline.
TemazepamThe metabolism of Temazepam can be decreased when combined with Sertraline.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Sertraline.
TeniposideThe metabolism of Teniposide can be decreased when combined with Sertraline.
TenofovirThe metabolism of Sertraline can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Sertraline can be decreased when combined with Terbinafine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sertraline.
TeriflunomideThe serum concentration of Sertraline can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Sertraline.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sertraline.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Sertraline.
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Sertraline.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Sertraline.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sertraline.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sertraline.
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sertraline.
TheophyllineThe metabolism of Sertraline can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertraline.
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Sertraline.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Sertraline.
ThioproperazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Sertraline.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sertraline.
ThiotepaThe metabolism of Sertraline can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Sertraline.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Sertraline.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Sertraline.
TianeptineThe risk or severity of adverse effects can be increased when Sertraline is combined with Tianeptine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Sertraline.
TicagrelorThe metabolism of Sertraline can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Sertraline can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Sertraline.
TimololThe serum concentration of Timolol can be increased when it is combined with Sertraline.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Sertraline.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Sertraline.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Sertraline.
TocilizumabThe serum concentration of Sertraline can be decreased when it is combined with Tocilizumab.
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Sertraline.
TolazamideSertraline may increase the hypoglycemic activities of Tolazamide.
TolbutamideSertraline may increase the hypoglycemic activities of Tolbutamide.
TolbutamideThe metabolism of Sertraline can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sertraline.
ToloxatoneToloxatone may increase the serotonergic activities of Sertraline.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sertraline.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Sertraline.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Sertraline.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sertraline.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Sertraline.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Sertraline.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Sertraline.
TramadolTramadol may increase the serotonergic activities of Sertraline.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Sertraline.
TranylcypromineTranylcypromine may increase the serotonergic activities of Sertraline.
TranylcypromineThe risk or severity of adverse effects can be increased when Sertraline is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Sertraline.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sertraline.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Sertraline.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sertraline.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Sertraline.
TrichlormethiazideSertraline may increase the hyponatremic activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertraline.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertraline.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sertraline.
TrimethoprimThe metabolism of Sertraline can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Sertraline.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Sertraline.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Sertraline.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sertraline.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Sertraline.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Sertraline.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sertraline.
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Sertraline.
ValsartanThe metabolism of Sertraline can be decreased when combined with Valsartan.
VandetanibSertraline may increase the QTc-prolonging activities of Vandetanib.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Sertraline.
VemurafenibThe serum concentration of Sertraline can be increased when it is combined with Vemurafenib.
VemurafenibSertraline may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Sertraline can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Sertraline.
VerapamilThe metabolism of Sertraline can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Sertraline.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Sertraline.
VilazodoneVilazodone may increase the serotonergic activities of Sertraline.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Sertraline.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Sertraline.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Sertraline.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Sertraline.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Sertraline.
VoriconazoleThe metabolism of Sertraline can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Sertraline.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Sertraline.
WarfarinSertraline may increase the anticoagulant activities of Warfarin.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Sertraline.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Sertraline.
ZafirlukastThe metabolism of Sertraline can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sertraline.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sertraline.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sertraline.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Sertraline.
ZimelidineSertraline may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Sertraline.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Sertraline.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sertraline.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Sertraline.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sertraline.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sertraline.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Sertraline.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Sertraline.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Sertraline.
Food Interactions
  • Avoid alcohol.
  • Avoid St.John's Wort.
  • Avoid taking with grapefruit juice.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A: Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci. 1999 Dec 1;19(23):10494-501. [PubMed:10575045 ]
  2. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A: Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci. 2002 Aug 1;22(15):6766-72. [PubMed:12151556 ]
  3. Borkowska A, Pilaczynska E, Araszkiewicz A, Rybakowski J: [The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]. Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):289-95. [PubMed:12647451 ]
  4. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004 Aug;174(4):525-9. Epub 2003 Sep 4. [PubMed:12955294 ]
  5. Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O: Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem. 2005 Jan;92(1):21-8. [PubMed:15606893 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  7. David DJ, Bourin M, Hascoet M, Colombel MC, Baker GB, Jolliet P: Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice. Psychopharmacology (Berl). 2001 Feb;153(4):443-9. [PubMed:11243491 ]
  8. Rogoz Z, Skuza G: Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol Rep. 2006 Jul-Aug;58(4):493-500. [PubMed:16963794 ]
  9. Muneoka K, Shirayama Y, Takigawa M, Shioda S: Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. Neurochem Res. 2009 Mar;34(3):542-55. doi: 10.1007/s11064-008-9818-2. Epub 2008 Aug 27. [PubMed:18751896 ]
  10. Iehle C, Delos S, Filhol O, Martin PM: Baculovirus-directed expression of human prostatic steroid 5 alpha-reductase 1 in an active form. J Steroid Biochem Mol Biol. 1993 Aug;46(2):177-82. [PubMed:8664165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  2. Ghanizadeh A: Sertraline-associated hair loss. J Drugs Dermatol. 2008 Jul;7(7):693-4. [PubMed:18664165 ]
  3. Lemke MR: [Antidepressant effects of dopamine agonists. Experimental and clinical findings]. Nervenarzt. 2007 Jan;78(1):31-8. [PubMed:17187269 ]
  4. Nemeroff CB, Owens MJ: Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr. 2004 Jun;9(6 Suppl 4):23-31. [PubMed:15181382 ]
  5. Goodnick PJ, Goldstein BJ: Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology. J Psychopharmacol. 1998;12(3 Suppl B):S5-20. [PubMed:9808077 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6. [PubMed:12143142 ]
  3. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940 ]
  4. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  3. Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6. [PubMed:12143142 ]
  4. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6. [PubMed:12143142 ]
  3. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  2. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Not Available
Gene Name:
CYP2B
Uniprot ID:
Q14097
Molecular Weight:
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 03:31